These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 26173185)

  • 1. Bayesian dose escalation in oncology with sharing of information between patient populations.
    Broglio KR; Sandalic L; Albertson T; Berry SM
    Contemp Clin Trials; 2015 Sep; 44():56-63. PubMed ID: 26173185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A simulation-based comparison of the traditional method, Rolling-6 design and a frequentist version of the continual reassessment method with special attention to trial duration in pediatric Phase I oncology trials.
    Onar-Thomas A; Xiong Z
    Contemp Clin Trials; 2010 May; 31(3):259-70. PubMed ID: 20298812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
    Gerke O; Siedentop H
    Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Continual Reassessment Method With Cohort Size Adaptation Based on Bayesian Posterior Probabilities in Phase I Dose-Finding Studies.
    Kakizume T; Morita S
    Ther Innov Regul Sci; 2014 Mar; 48(2):213-219. PubMed ID: 30227515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exposure driven dose escalation design with overdose control: Concept and first real life experience in an oncology phase I trial.
    Micallef S; Sostelly A; Zhu J; Baverel PG; Mercier F
    Contemp Clin Trials Commun; 2022 Apr; 26():100901. PubMed ID: 35198796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pediatric phase I trials in oncology: an analysis of study conduct efficiency.
    Lee DP; Skolnik JM; Adamson PC
    J Clin Oncol; 2005 Nov; 23(33):8431-41. PubMed ID: 16293874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose Finding for Drug Combination in Early Cancer Phase I Trials using Conditional Continual Reassessment Method.
    Diniz MA; Quanlin-Li ; Tighiouart M
    J Biom Biostat; 2017; 8(6):. PubMed ID: 29552377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Designing phase I oncology dose escalation using dose-exposure-toxicity models as a complementary approach to model-based dose-toxicity models.
    Pantoja K; Lanke S; Munafo A; Victor A; Habermehl C; Schueler A; Venkatakrishnan K; Girard P; Goteti K
    CPT Pharmacometrics Syst Pharmacol; 2022 Oct; 11(10):1371-1381. PubMed ID: 35852048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Bayesian Adaptive Design in Cancer Phase I Trials Using Dose Combinations with Ordinal Toxicity Grades.
    Diniz MA; Kim S; Tighiouart M
    Stats (Basel); 2020 Sep; 3(3):221-238. PubMed ID: 33073179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies.
    Iasonos A; Wilton AS; Riedel ER; Seshan VE; Spriggs DR
    Clin Trials; 2008; 5(5):465-77. PubMed ID: 18827039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancer.
    Potter DM
    Stat Med; 2002 Jul; 21(13):1805-23. PubMed ID: 12111891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.
    Normolle D; Lawrence T
    J Clin Oncol; 2006 Sep; 24(27):4426-33. PubMed ID: 16983110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.
    Rinaldi DA; Kuhn JG; Burris HA; Dorr FA; Rodriguez G; Eckhardt SG; Jones S; Woodworth JR; Baker S; Langley C; Mascorro D; Abrahams T; Von Hoff DD
    Cancer Chemother Pharmacol; 1999; 44(5):372-80. PubMed ID: 10501910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study.
    Kieran MW; Packer RJ; Onar A; Blaney SM; Phillips P; Pollack IF; Geyer JR; Gururangan S; Banerjee A; Goldman S; Turner CD; Belasco JB; Broniscer A; Zhu Y; Frank E; Kirschmeier P; Statkevich P; Yver A; Boyett JM; Kun LE
    J Clin Oncol; 2007 Jul; 25(21):3137-43. PubMed ID: 17634493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of EWOC principle in BLRM design for phase 1 oncology trials.
    Guo X; Kent S; Maity A; Zhong W
    J Biopharm Stat; 2024 Apr; ():1-17. PubMed ID: 38562014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PA-CRM: A continuous reassessment method for pediatric phase I oncology trials with concurrent adult trials.
    Li Y; Yuan Y
    Biometrics; 2020 Dec; 76(4):1364-1373. PubMed ID: 31950483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of the continual reassessment method to a phase I dose-finding trial in Japanese patients: East meets West.
    Morita S
    Stat Med; 2011 Jul; 30(17):2090-7. PubMed ID: 21500239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Escalation with overdose control for phase I drug-combination trials.
    Shi Y; Yin G
    Stat Med; 2013 Nov; 32(25):4400-12. PubMed ID: 23630103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.
    Paoletti X; Kramar A
    Stat Med; 2009 Oct; 28(24):3012-28. PubMed ID: 19672839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bridging continual reassessment method for phase I clinical trials in different ethnic populations.
    Liu S; Pan H; Xia J; Huang Q; Yuan Y
    Stat Med; 2015 May; 34(10):1681-94. PubMed ID: 25626429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.